Spore Biotechnologies is excited to announce a successful funding round, raising $23,000,000 to further accelerate the next-generation of genetic testing innovations. As a leading global biotechnology company, Stilla Technologies has been at the forefront of revolutionizing high-resolution genetic analysis and assay development through their proprietary Multiplex Crystal Digital PCR™ technology. With cutting-edge microfluidic innovations that integrate the entire digital PCR process on a single chip, the naica® system represents a leap forward in sensitivity, speed, and workflow simplicity. This fresh capital infusion will empower the company to broaden its research and development initiatives, ensuring that its advanced digital PCR solutions become accessible and indispensable across a wide array of life science applications.
The funds will be strategically deployed to enhance assay performance, expand multiplexing capabilities, and accelerate the development of tools crucial for cancer research, liquid biopsy studies, cell and gene therapies, infectious disease monitoring—including COVID-19—and even environmental applications such as wastewater testing. By prioritizing continued innovation and improving the ease-of-use of its technology, Spore Biotechnologies is poised to make Digital PCR a laboratory staple, drastically reducing turnaround times and lowering barriers for researchers and clinicians globally. This investment not only underscores confidence in their pioneering approach but also marks a significant milestone in bridging advanced research and practical, everyday lab applications. To learn more about the groundbreaking work at Stilla Technologies and join the conversation, visit our website and connect with us on Twitter at @StillaTech.
.png&w=3840&q=75)
